Aug 27, 2009
Fast Forward Contracts With IntraLinks to Accelerate and Facilitate Its Drug Funding Decisions
Fast Forward has chosen IntraLinks®, a leading provider of critical information exchange solutions to help streamline the collection, distribution and tracking of information needed to support its funding of multiple biotechnology and pharmaceutical companies who are working on new MS treatments.
“We believe using IntraLinks facilitates our evaluation and management of the complex data related to prospective drugs in the development pipeline. This increases our ability to make funding decisions that will expedite new treatments to the people who need them,” said Maya Merrell, business manager for Fast Forward.
IntraLinks’ simplifies the exchange of information between everyone involved in the Fast Forward due diligence and funding process—from board members to scientific and business advisors and other external constituents. It also streamlines that whole process—crucial for the small staff at Fast Forward and its work teams based in different locations.
“Often times, companies involved in research and technology development have difficulty securing funds to move scientific ideas from discovery into preclinical development,” said Allison Shurell, vice president of product marketing for IntraLinks." We’re helping Fast Forward close the funding gap which had previously slowed the drug development process for MS.”
Fast Forward is currently using 16 active IntraLinks ExchangesTM to manage global funding opportunities.
About IntraLinks
IntraLinks provides on-demand solutions for businesses to securely collaborate, communicate and exchange critical information inside and outside the enterprise. For more than a decade, 750,000 professionals from more than 90,000 organizations have relied on IntraLinks to accelerate workflow, optimize business processes and realize new profit potential. IntraLinks counts 800 of the Fortune 1000 as clients, including AstraZeneca Pharmaceuticals LP, Bank of America, Deutsche Bank and the FDIC. For more information, visit www.intralinks.com.
About Fast Forward, LLC
Fast Forward, LLC is a nonprofit organization established by the National Multiple Sclerosis Society in order to accelerate the development of treatments for MS. Fast Forward will accomplish its mission by connecting university-based MS research with private-sector drug development and by funding small biotechnology/pharmaceutical companies to develop innovative new MS therapies and repurpose FDA-approved drugs as new treatments for MS. For more information, visit www.fastforward.org.